Recent advances in Huntington's disease: Implications for experimental therapeutics

Andrew Feigin, Dennis Zgaljardic

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Purpose of review: In this article we have set out to critically review recent advances in the basic and clinical understanding of Huntington's disease, with specific emphasis on those findings that are most relevant to the planning, design, and conduct of future clinical trials for this devastating disorder. Recent findings: The exact mechanisms underlying neuronal death in Huntington's disease remain unknown. Over the past 10 years, the leading models of neurodegeneration in the disease have involved mitochondrial dysfunction and subsequent excitotoxic injury, oxidative stress, and apoptosis. Recent studies have lent support to these models, but additional theories involving abnormalities of protein metabolism and transcriptional dysregulation have emerged as well. As progress is made toward clarifying the pathophysiological mechanisms leading to Huntington's disease, and new therapies are proposed, investigators have begun to develop improved outcome measures for potential use in future clinical trials aimed at slowing the progression of the disorder. Summary: Recent advances in the understanding of the molecular biology and pathophysiology of Huntington's disease have suggested new therapeutic strategies aimed at slowing progression or forestalling onset of this neurodegenerative disease. In preparation for future clinical trials, clinical studies have begun to provide more quantitative measures of disease onset and progression. This progress in both the basic science and clinical realms raises real hope for effective therapies in the near future.

Original languageEnglish (US)
Pages (from-to)483-489
Number of pages7
JournalCurrent Opinion in Neurology
Volume15
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Huntington Disease
Clinical Trials
Therapeutics
Neurodegenerative Diseases
Disease Progression
Molecular Biology
Oxidative Stress
Research Personnel
Outcome Assessment (Health Care)
Apoptosis
Wounds and Injuries
Proteins

Keywords

  • Clinical progression
  • Experimental therapeutics
  • Huntington's disease
  • Pathophysiology

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Recent advances in Huntington's disease : Implications for experimental therapeutics. / Feigin, Andrew; Zgaljardic, Dennis.

In: Current Opinion in Neurology, Vol. 15, No. 4, 2002, p. 483-489.

Research output: Contribution to journalReview article

Feigin, Andrew ; Zgaljardic, Dennis. / Recent advances in Huntington's disease : Implications for experimental therapeutics. In: Current Opinion in Neurology. 2002 ; Vol. 15, No. 4. pp. 483-489.
@article{c85e0f3710084a8cb9699a3b3b1174e3,
title = "Recent advances in Huntington's disease: Implications for experimental therapeutics",
abstract = "Purpose of review: In this article we have set out to critically review recent advances in the basic and clinical understanding of Huntington's disease, with specific emphasis on those findings that are most relevant to the planning, design, and conduct of future clinical trials for this devastating disorder. Recent findings: The exact mechanisms underlying neuronal death in Huntington's disease remain unknown. Over the past 10 years, the leading models of neurodegeneration in the disease have involved mitochondrial dysfunction and subsequent excitotoxic injury, oxidative stress, and apoptosis. Recent studies have lent support to these models, but additional theories involving abnormalities of protein metabolism and transcriptional dysregulation have emerged as well. As progress is made toward clarifying the pathophysiological mechanisms leading to Huntington's disease, and new therapies are proposed, investigators have begun to develop improved outcome measures for potential use in future clinical trials aimed at slowing the progression of the disorder. Summary: Recent advances in the understanding of the molecular biology and pathophysiology of Huntington's disease have suggested new therapeutic strategies aimed at slowing progression or forestalling onset of this neurodegenerative disease. In preparation for future clinical trials, clinical studies have begun to provide more quantitative measures of disease onset and progression. This progress in both the basic science and clinical realms raises real hope for effective therapies in the near future.",
keywords = "Clinical progression, Experimental therapeutics, Huntington's disease, Pathophysiology",
author = "Andrew Feigin and Dennis Zgaljardic",
year = "2002",
doi = "10.1097/00019052-200208000-00013",
language = "English (US)",
volume = "15",
pages = "483--489",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Recent advances in Huntington's disease

T2 - Implications for experimental therapeutics

AU - Feigin, Andrew

AU - Zgaljardic, Dennis

PY - 2002

Y1 - 2002

N2 - Purpose of review: In this article we have set out to critically review recent advances in the basic and clinical understanding of Huntington's disease, with specific emphasis on those findings that are most relevant to the planning, design, and conduct of future clinical trials for this devastating disorder. Recent findings: The exact mechanisms underlying neuronal death in Huntington's disease remain unknown. Over the past 10 years, the leading models of neurodegeneration in the disease have involved mitochondrial dysfunction and subsequent excitotoxic injury, oxidative stress, and apoptosis. Recent studies have lent support to these models, but additional theories involving abnormalities of protein metabolism and transcriptional dysregulation have emerged as well. As progress is made toward clarifying the pathophysiological mechanisms leading to Huntington's disease, and new therapies are proposed, investigators have begun to develop improved outcome measures for potential use in future clinical trials aimed at slowing the progression of the disorder. Summary: Recent advances in the understanding of the molecular biology and pathophysiology of Huntington's disease have suggested new therapeutic strategies aimed at slowing progression or forestalling onset of this neurodegenerative disease. In preparation for future clinical trials, clinical studies have begun to provide more quantitative measures of disease onset and progression. This progress in both the basic science and clinical realms raises real hope for effective therapies in the near future.

AB - Purpose of review: In this article we have set out to critically review recent advances in the basic and clinical understanding of Huntington's disease, with specific emphasis on those findings that are most relevant to the planning, design, and conduct of future clinical trials for this devastating disorder. Recent findings: The exact mechanisms underlying neuronal death in Huntington's disease remain unknown. Over the past 10 years, the leading models of neurodegeneration in the disease have involved mitochondrial dysfunction and subsequent excitotoxic injury, oxidative stress, and apoptosis. Recent studies have lent support to these models, but additional theories involving abnormalities of protein metabolism and transcriptional dysregulation have emerged as well. As progress is made toward clarifying the pathophysiological mechanisms leading to Huntington's disease, and new therapies are proposed, investigators have begun to develop improved outcome measures for potential use in future clinical trials aimed at slowing the progression of the disorder. Summary: Recent advances in the understanding of the molecular biology and pathophysiology of Huntington's disease have suggested new therapeutic strategies aimed at slowing progression or forestalling onset of this neurodegenerative disease. In preparation for future clinical trials, clinical studies have begun to provide more quantitative measures of disease onset and progression. This progress in both the basic science and clinical realms raises real hope for effective therapies in the near future.

KW - Clinical progression

KW - Experimental therapeutics

KW - Huntington's disease

KW - Pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=0036312181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036312181&partnerID=8YFLogxK

U2 - 10.1097/00019052-200208000-00013

DO - 10.1097/00019052-200208000-00013

M3 - Review article

C2 - 12151847

AN - SCOPUS:0036312181

VL - 15

SP - 483

EP - 489

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 4

ER -